Drug intelligence / Profile preview

EB-Vac1

Development stage: Preclinical
Lead developer: Exollence
Modality: Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

EB-Vac1 is an exosome-based vaccine candidate being developed by Exollence Biotechnology for the prevention of viral infections, including COVID-19, influenza, and respiratory syncytial virus (RSV). The vaccine utilizes aTHP-1 cell-derived exosomes as a delivery vehicle for viral antigen proteins or mRNA. This approach is designed to induce a targeted immune response against the specific viral pathogens. EB-Vac1 is currently in the discovery stage and is intended for subcutaneous administration.

Beyond the preview

Go deeper on EB-Vac1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB-Vac1.

Explore the full profile